Clin2
NCT07104721Worth exploringRecruiting

YTS109 cell therapy for severe autoimmune diseases

Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)Systemic Sclerosis (SSc)Inflammatory MyopathyAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisAntiphospholipid Syndrome (APS)

Treatments studied

Part of Bones, joints & muscles, Brain & nervous system, Heart & circulation, Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.

This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity in conditions like lupus, Sjögren's syndrome, and others.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
18 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You are between 18 and 65 years old.
  • You have a specific autoimmune disease that has not improved with standard treatments for at least 6 months.
  • Your bone marrow, liver, kidneys, and heart are working well enough (based on recent blood tests).
  • You are not pregnant, and you agree to use birth control during the study and for 12 months after.
  • You have not had certain infections (like active hepatitis, HIV, or syphilis) or a history of cancer in the last 5 years.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07236762Recruiting· Phase 1
YTS109 cell therapy for severe autoimmune diseases

This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases like lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. It's for those whose disease hasn't improved with standard treatments.

Bengbu
NCT07123519Recruiting· Phase 1
YTS109 cell therapy for hard-to-treat autoimmune diseases

This trial tests a new cell therapy called YTS109 for people with certain severe autoimmune diseases that have not responded to standard treatments, such as lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. The goal is to see if it can safely reduce disease activity.

Tianjin
NCT06978647Recruiting· Phase 1
YTS109 cell therapy for stubborn autoimmune diseases

This trial tests a new cell therapy called YTS109 for people with certain autoimmune diseases like lupus that have not improved with standard treatments. It aims to see if this therapy can help control disease activity.

Beijing, Beijing Municipality
NCT07236801Recruiting· Phase 1
Cell therapy for hard-to-treat autoimmune diseases

This trial tests a new cell therapy called YTS109 for people with several autoimmune diseases that have not improved with standard medications. It aims to see if this treatment can help control the disease when other treatments have failed.

Xuzhou, Jiangsu
NCT06379646Recruiting
YTS109 cell therapy for autoimmune disease

This study tests a new cell therapy (YTS109) for people with autoimmune diseases like lupus or Sjogren's syndrome that have not improved or keep coming back after standard treatments. It aims to see if the treatment can help control the disease.

Shanghai, Shanghai Municipality
NCT07439029Not yet recruiting· Phase 1
YTS109 for children with hard-to-treat autoimmune diseases

This trial studies a new treatment called YTS109 for children aged 5 to 18 with certain autoimmune diseases that have not gotten better with standard therapies. The treatment targets and possibly removes a type of immune cell that may be causing the disease.

Shanghai

Hear when a new Systemic Sclerosis (SSc) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.